Remove Cannabinoids Remove Data Remove Patients Remove Pharmaceutical
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Patients who suffer from epilepsy , which affects some 3.4 million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated.

Sleep 133
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We could potentially develop north of 11,000 drugs that are cannabinoid-based. “We know cannabis has powerful potential medical effects.

article thumbnail

States That Restrict MMJ Access Are Interfering With Patients’ Rights, Study Shows

Veriheal

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.